Ibex, AstraZeneca, and Daiichi Sankyo Enter into a Collaboration to Develop Galen Breast HER2 for the Detection of Breast Cancer
- The companies will jointly develop, clinically validate & adopt Galen Breast HER2, to assist pathologists to perform accurate & reproducible assessments of HER2 IHC scoring in breast cancer patients
- As per the results (presented at SABCS 2022) from the multi-site validation study evaluating Galen Breast HER2 in cohorts of 453 breast tumors, Galen's AI algorithm provided an accurate & automated HER2 score for pathologists
- Ibex’s Galen Breast HER2 is an IHC-scoring product that detects tumor areas & quantifies HER2 expression into 4 categories (0, 1+, 2+ & 3+). Ibex expects to expand Galen Breast to include automated quantification of additional IHC-stained slides (i.e. ER, PR & Ki-67) to aid pathologists in breast cancer diagnosis
Ref: PR Newswire | Image: Ibex
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.